Aidian Oy signs exclusive European distribution agreement with Qlife for Egoo.Health device and SARS-CoV-2 capsules
The agreement covers a range of European countries, including Sweden, Norway, Finland, Germany, Netherlands, Belgium, Luxembourg, Austria, Switzerland, Poland, Czech Republic, Hungary, Slovakia, Romania, Slovenia, and Baltics, and applies immediately.
Qlife is a medical device company that seeks to revolutionize the clinical biomarker market with their small Egoo.Health analyzer and test capsules. The Egoo.Health rapid molecular test for detection of SARS-CoV-2 delivers a result in 30 minutes with less than a minute of hands-on time to prepare the sample. The SARS-CoV-2 test can be utilized in multiple settings where actionable test results are needed to make informed treatment decisions quickly. The test delivers near-patient results with the same level of performance as in reference labs.
The Egoo.Health SARS-CoV-2 assay utilizes Aidian’s proprietary isothermal amplification technology SIBA® (Strand Invasion Based Amplification). “Aidian's SIBA® technology, together with the Qlife's Egoo.Health platform bring to life a high-quality and compact molecular assay for detection of SARS-CoV-2", comments Juho Himberg, CEO of Aidian. "This combination of a small analyzer with the robust SIBA assay enables easy access molecular COVID-19 testing without high investment needs for larger instrumentation and the product is a great fit to our European wide customer base. We look forward to the collaboration and a partnership for the future that will focus on bringing more test capsules to the market", concludes Himberg.